56 results
Page 2 of 3
6-K
EX-5.2
mfn6 ovf466d8sfq3ki
1 Mar 21
Current report (foreign)
12:00am
6-K
EX-99.1
u7q8x8rkz
1 Mar 21
Current report (foreign)
12:00am
424B5
zvgtzed5
26 Feb 21
Prospectus supplement for primary offering
5:10pm
424B5
rmczak15
24 Feb 21
Prospectus supplement for primary offering
5:16pm
6-K
eweibo5ae6kmea8f8
24 Feb 21
Current report (foreign)
4:16pm
6-K
EX-99.2
oguy1k fpyypo4pv
11 Jan 21
InflaRx Provides Update on Vilobelimab (IFX-1) Development
7:30am
6-K
EX-99.2
wmlebqfr zh
29 Oct 20
Current report (foreign)
7:05am
S-8
l4jdf6wpi4pmw7beh cy
30 Jul 20
Registration of securities for employees
8:39am
6-K
EX-99.3
v088 01zqed
30 Jul 20
Current report (foreign)
7:36am
6-K
EX-99.1
kssai2o9mz8 53u
30 Jul 20
Current report (foreign)
7:36am
6-K
EX-99.2
1zg6nmav
30 Jul 20
Current report (foreign)
7:36am
424B5
dmqdd
20 Jul 20
Prospectus supplement for primary offering
9:21am
6-K
EX-99.1
8muk23q gpxd0cxancx
20 Jul 20
from 6-K
9:02am
F-3/A
wr2yh03b4ki4zp40mq5g
16 Jul 20
Shelf registration (foreign) (amended)
9:33am
F-3
EX-5.2
o85moqyizs ch843
8 Jul 20
Shelf registration (foreign)
12:00am
F-3
lxd 0445kz
8 Jul 20
Shelf registration (foreign)
12:00am
6-K
wlf94f8hh5dv
30 Jun 20
Current report (foreign)
6:38am